HA (7) E2F -1   IB   R38Q  T84K  D100Y  R101L  C151S  S160R  R185H  F269L  R288G  R288*  K313N  R333*  R357Q  A406S A406V Q415H Figure S1 (A) (i) Quantification of percentages of U2OS cells in the different phases of the cell cycle, as described (Figure 1Bi) ; data represent the mean of three replicates.
(ii) Levels of E2F-7 were analysed by immunoblotting. GAPDH served as a loading control.
(iii) Flow cytometry profiles representing the cell cycle phase for the BrdU-stained cells.
(B) (i) Flow cytometry profiles of U2OS cells treated as described ( Figure 1C) representing cell cycle phase for the total cell population and for the BrdU-stained cells, as indicated.
(ii) Levels of E2F-7 were analysed by immunoblotting. GAPDH served as a loading control. (B) Protein levels of E2F-7 (7) and RAD51 (R), as described ( Figure 2B ), were analysed by immunoblotting; GAPDH served as a loading control. HA-ISceI levels are also indicated.
(C) (i) U2OS DR-GFP cells were treated with non-targeting (NT) or E2F-7 siRNA and transfected with control vector (-) or increasing amounts of HA-ISceI (µg), as indicated.
The results represent the level of GFP intensity, normalised for transfection efficiency, as measured by flow cytometry. Error bars, SD (n=3). Statistical analysis by unpaired t-test ( *** =p≤0.001, ** =p≤0.01) (ii) Protein levels of E2F-7 were analysed by immunoblotting; GAPDH served as a loading control. HA-ISceI levels are also indicated.
(D) (i) U2OS DR-GFP cells were treated with NT, E2F-7 or E2F-1 siRNA and transfected with control vector (-) or HA-ISceI (+), as indicated. The results represent the level of GFP intensity, normalised for transfection efficiency, as measured by flow cytometry. Error bars, SD (n=3). Statistical analysis by unpaired t-test ( *** =p≤0.001).
